CA2818593A1 - Prognostic biomarkers in patients with ovarian cancer - Google Patents

Prognostic biomarkers in patients with ovarian cancer Download PDF

Info

Publication number
CA2818593A1
CA2818593A1 CA2818593A CA2818593A CA2818593A1 CA 2818593 A1 CA2818593 A1 CA 2818593A1 CA 2818593 A CA2818593 A CA 2818593A CA 2818593 A CA2818593 A CA 2818593A CA 2818593 A1 CA2818593 A1 CA 2818593A1
Authority
CA
Canada
Prior art keywords
biomarkers
ovarian cancer
subject
sample
prognosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2818593A
Other languages
English (en)
French (fr)
Inventor
Estrid Hogdall
Eric T. Fung
Ib Jarle Christensen
Claus Hogdall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aspira Womens Health Inc
Original Assignee
Vermillion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vermillion Inc filed Critical Vermillion Inc
Publication of CA2818593A1 publication Critical patent/CA2818593A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57449Specifically defined cancers of ovaries
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/88Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416Systems
    • G01N27/447Systems using electrophoresis
    • G01N27/44756Apparatus specially adapted therefor
    • G01N27/44773Multi-stage electrophoresis, e.g. two-dimensional electrophoresis
    • G01N27/44778Multi-stage electrophoresis, e.g. two-dimensional electrophoresis on a common gel carrier, i.e. 2D gel electrophoresis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA2818593A 2010-10-22 2011-10-21 Prognostic biomarkers in patients with ovarian cancer Abandoned CA2818593A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40604410P 2010-10-22 2010-10-22
US61/406,044 2010-10-22
PCT/US2011/057271 WO2012054824A2 (en) 2010-10-22 2011-10-21 Prognostic biomarkers in patients with ovarian cancer

Publications (1)

Publication Number Publication Date
CA2818593A1 true CA2818593A1 (en) 2012-04-26

Family

ID=45975910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2818593A Abandoned CA2818593A1 (en) 2010-10-22 2011-10-21 Prognostic biomarkers in patients with ovarian cancer

Country Status (5)

Country Link
EP (1) EP2630498A4 (enExample)
JP (2) JP2013541716A (enExample)
AU (1) AU2011316844A1 (enExample)
CA (1) CA2818593A1 (enExample)
WO (1) WO2012054824A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3210220A1 (en) * 2013-05-10 2014-11-13 Johns Hopkins University Compositions for ovarian cancer assessment having improved specificity
WO2015163424A1 (ja) 2014-04-23 2015-10-29 株式会社ニチレイバイオサイエンス 標的マーカー検出用組合せ物
EP3435379A1 (en) * 2017-07-27 2019-01-30 Roche Diagnostics GmbH Augmenting measurement values of biological samples
WO2019088709A2 (ko) * 2017-10-31 2019-05-09 국립암센터 Nc886 유전자를 이용한 난소암 예후 예측을 위한 정보제공방법
JP7272627B2 (ja) * 2019-01-24 2023-05-12 公立大学法人和歌山県立医科大学 卵巣腫瘍の評価用バイオマーカー
EP3980764A4 (en) * 2019-06-06 2023-07-05 Icahn School of Medicine at Mount Sinai SYSTEMS AND METHODS FOR DIAGNOSIS OF BIOLOGICAL DISEASES RELATED TO PERIODIC VARIATIONS OF METAL METABOLISM

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1540010B8 (en) * 2002-08-06 2010-07-14 The Johns Hopkins University Use of biomarkers for detecting ovarian cancer
DK2199801T3 (da) * 2004-07-14 2013-08-05 Univ California Biomarkører til tidlig påvisning af ovariecancer
NZ560976A (en) * 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
EP2993474B1 (en) * 2005-06-24 2019-06-12 Vermillion, Inc. Biomarkers for ovarian cancer: beta-2 microglobulin
WO2008060376A2 (en) * 2006-10-04 2008-05-22 The Johns Hopkins University Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
WO2008048508A2 (en) * 2006-10-13 2008-04-24 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
EP2637020A3 (en) * 2007-06-29 2014-01-08 Correlogic Systems Inc. Predictive markers for ovarian cancer
JP5391400B2 (ja) * 2007-10-01 2014-01-15 公益財団法人ヒューマンサイエンス振興財団 α−アクチニン−4遺伝子のコピー数または発現レベルを指標とした膵癌の検出を補助する方法および診断のためのキット
WO2009058331A2 (en) * 2007-10-29 2009-05-07 Vermilllion, Inc. Biomarkers for the detection of early stage ovarian cancer
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis

Also Published As

Publication number Publication date
JP2016212116A (ja) 2016-12-15
WO2012054824A3 (en) 2012-07-19
JP2013541716A (ja) 2013-11-14
AU2011316844A1 (en) 2013-06-06
WO2012054824A2 (en) 2012-04-26
EP2630498A2 (en) 2013-08-28
EP2630498A4 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
KR101107765B1 (ko) 난소암의 검출을 위한 생물 마커의 용도
US8682591B2 (en) Biomarkers for ovarian cancer
US20170089906A1 (en) Biomarkers for ovarian cancer
US20100055690A1 (en) Prognostic biomarkers in patients with ovarian cancer
US20140038837A1 (en) Biomarkers for the detection of early stage ovarian cancer
JP2016212116A (ja) 卵巣癌の患者における予後予測バイオマーカー
US20100068818A1 (en) Algorithms for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
EP2994542A1 (en) Compositions for ovarian cancer assessment having improved specificity
US20100197561A1 (en) Biomarkers for Ovarian Cancer: B2 Microglobulin
US20090142332A1 (en) Identification of Biomarkers by Serum Protein Profiling
AU2008236810A1 (en) Biomarkers for ovarian cancer
WO2007133957A1 (en) Biomarkers for mesothelioma: apoc1 and apoa2
US20150126384A1 (en) Prognostic Biomarkers in Patients with Ovarian Cancer
US20210215701A1 (en) Compositions for ovarian cancer assessment
HK40102817A (en) Compositions for ovarian cancer assessment having improved specificity
WO2006071843A2 (en) Biomarkers for breast cancer
US20150153348A1 (en) BIOMARKERS FOR OVARIAN CANCER: Beta 2 MICROGLOBULIN

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160927

FZDE Discontinued

Effective date: 20190801